Oncology Data Advisor - Data Hub: Hematologic Malignancies

Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD

At this year's IMS Meeting, Dr. Shonali Midha presented real-world data of teclistamab for relapsed/refractory multiple myeloma. After the meeting, OncData Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates on bispecific antibodies presented.

$Multidisciplinary Task Force: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma$

Multidisciplinary Task Force: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma

With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ ...

Venetoclax for Multiple Myeloma in the Post-CANOVA Era With Rahul Banerjee, MD, FACP, and Andrew Yee, MD

At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee,...

Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD

At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting...

Venetoclax for Multiple Myeloma in the Post-CANOVA Era With Rahul Banerjee, MD, FACP, and Andrew Yee, MD

Oncology Data Advisor® · Venetoclax for Multiple Myeloma in the Post-CANOVA Era: Rahul Banerjee, MD, FACP, and Andrew Yee, MD At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the...

Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD

Oncology Data Advisor® · Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023: Rahul Banerjee and Shonali Midha At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at H...

World Cancer Research Day With Samuel Kareff, MD, MPH; Maria Badillo, RN; Matthew Hadfield, DO; and Alankrita Taneja, MD

Oncology Data Advisor® · World Cancer Research Day With Samuel Kareff, Maria Badillo, Matthew Hadfield, and Alankrita Taneja In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined...

Oncology Data Advisor® Appoints Rahul Banerjee, MD, FACP, as Editor in Chief for New Term

Oncology Data Advisor® has appointed Rahul Banerjee, MD, FACP, as Editor in Chief for its next term. Dr. Banerjee is an Assistant Professor of Medicine in the Division of Oncology at the University of Washington, Fred Hutchinson Cancer Center in Seat...

Bosutinib Approved for Pediatric Patients With Chronic Myelogenous Leukemia

The FDA has approved bosutinib (Bosulif®, Pfizer) for treatment of pediatric patients with newly diagnosed or resistant/intolerant to prior therapy chronic phase (CP) Philadelphia chromosome (Ph)–positive chronic myelogenous leukemia (CML). In additi...

Confronting Knowledge Gaps in Rare Hematologic Malignancies

In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians rega...